Design of peptide and polypeptide vaccines (Q41572759)

4 October 2017

1 reference

title

Design of peptide and polypeptide vaccines (English)

1 reference

4 October 2017

T. Ben-Yedidia

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:9265723

12 November 2024

R. Arnon

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:9265723

12 November 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=9265723

12 November 2024

publication date

1 August 1997

1 reference

4 October 2017

August 1997

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=9265723

full work available at URL

12 November 2024

https://api.elsevier.com/content/article/PII:S0958166997800663?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S0958-1669(97)80066-3

https://api.elsevier.com/content/article/PII:S0958166997800663?httpAccept=text/plain

12 November 2024

1 reference

https://api.crossref.org/works/10.1016/S0958-1669(97)80066-3

Current Opinion in Biotechnology

12 November 2024

published in

1 reference

4 October 2017

volume

8

1 reference

4 October 2017

issue

4

1 reference

4 October 2017

page(s)

442-448

1 reference

The influence of different adjuvants on the immune response to a synthetic peptide comprising amino acid residues 9-21 of herpes simplex virus type 1 glycoprotein D.

4 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/S0958-1669(97)80066-3

7 January 2021

Expression and immunogenicity of an 18-residue epitope of HIV1 gp41 inserted in the flagellar protein of a Salmonella live vaccine

1 reference

https://api.crossref.org/works/10.1016/S0958-1669(97)80066-3

7 January 2021

Immunogenicity of recombinant influenza virus haemagglutinin carrying peptides from the envelope protein of human immunodeficiency virus type 1

1 reference

https://api.crossref.org/works/10.1016/S0958-1669(97)80066-3

7 January 2021

Protective cross-reactive epitope on the nonstructural protein NS1 of influenza A virus

1 reference

https://api.crossref.org/works/10.1016/S0958-1669(97)80066-3

7 January 2021

Efficient antigen presentation to cytotoxic T lymphocytes by cells transduced with a retroviral vector expressing the HIV-1 Nef protein

1 reference

https://api.crossref.org/works/10.1016/S0958-1669(97)80066-3

7 January 2021

Old microbes with new faces: molecular biology and the design of new vaccines

1 reference

https://api.crossref.org/works/10.1016/S0958-1669(97)80066-3

7 January 2021

Efficacy of nucleoprotein and haemagglutinin antigens expressed in fowlpox virus as vaccine for influenza in chickens

1 reference

https://api.crossref.org/works/10.1016/S0958-1669(97)80066-3

7 January 2021

Retrovirus-expressed hemagglutinin protects against lethal influenza virus infections

1 reference

https://api.crossref.org/works/10.1016/S0958-1669(97)80066-3

7 January 2021

Relationship between antigenicity and immunogenicity of chimeric hepatitis B virus core particles carrying HIV type 1 epitopes

1 reference

https://api.crossref.org/works/10.1016/S0958-1669(97)80066-3

7 January 2021

Recent advances in multiple antigen peptides

1 reference

https://api.crossref.org/works/10.1016/S0958-1669(97)80066-3

7 January 2021

A dose-ranging study of a prototype synthetic HIV-1MN V3 branched peptide vaccine. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group

1 reference

https://api.crossref.org/works/10.1016/S0958-1669(97)80066-3

7 January 2021

A synthetic peptide-based polyoxime vaccine construct of high purity and activity

1 reference

https://api.crossref.org/works/10.1016/S0958-1669(97)80066-3

7 January 2021

Immunopotentiation of local and systemic humoral immune responses by ISCOMs, liposomes and FCA: role in protection against influenza A in mice

1 reference

https://api.crossref.org/works/10.1016/S0958-1669(97)80066-3

7 January 2021

ISCOMs (immunostimulating complexes): the first decade

1 reference

https://api.crossref.org/works/10.1016/S0958-1669(97)80066-3

7 January 2021

Linkage of a fusion peptide to a CTL epitope from the nucleoprotein of measles virus enables incorporation into ISCOMs and induction of CTL responses following intranasal immunization

1 reference

https://api.crossref.org/works/10.1016/S0958-1669(97)80066-3

7 January 2021

Synthetic recombinant vaccine expressing influenza haemagglutinin epitope in Salmonella flagellin leads to partial protection in mice

1 reference

https://api.crossref.org/works/10.1016/S0958-1669(97)80066-3

7 January 2021

Intranasal immunization of mice against influenza with synthetic peptides anchored to proteosomes

1 reference

https://api.crossref.org/works/10.1016/S0958-1669(97)80066-3

7 January 2021

Preclinical efficacy of a prototype DNA vaccine: Enhanced protection against antigenic drift in influenza virus

1 reference

https://api.crossref.org/works/10.1016/S0958-1669(97)80066-3

7 January 2021

DNA vaccines: a novel approach to immunization.

1 reference

https://api.crossref.org/works/10.1016/S0958-1669(97)80066-3

7 January 2021

Overview of DNA vaccines

1 reference

https://api.crossref.org/works/10.1016/S0958-1669(97)80066-3

7 January 2021

In vivo induction of cytotoxic T lymphocytes specific for a single epitope introduced into an unrelated molecule

1 reference

https://api.crossref.org/works/10.1016/S0958-1669(97)80066-3

7 January 2021

Helper and Cytotoxic T Cell Responses of HIV Type 1-Infected Individuals to Synthetic Peptides of HIV Type 1 Rev

1 reference

https://api.crossref.org/works/10.1016/S0958-1669(97)80066-3

7 January 2021

The mixotope: a combinatorial peptide library as a T cell and B cell immunogen.

1 reference

https://api.crossref.org/works/10.1016/S0958-1669(97)80066-3

7 January 2021

Priming of measles virus-specific CTL responses after immunization with a CTL epitope linked to a fusogenic peptide

1 reference

https://api.crossref.org/works/10.1016/S0958-1669(97)80066-3

7 January 2021

Identification of helper T cell antigenic sites in mice from the haemagglutinin glycoprotein of measles virus.

1 reference

https://api.crossref.org/works/10.1016/S0958-1669(97)80066-3

7 January 2021

Analysis of the antigenic profile of measles virus haemagglutinin in mice and humans using overlapping synthetic peptides

1 reference

https://api.crossref.org/works/10.1016/S0958-1669(97)80066-3

7 January 2021

Specificity of antibodies reactive with hepatitis B surface antigen following immunization with synthetic peptides

1 reference

https://api.crossref.org/works/10.1016/S0958-1669(97)80066-3

7 January 2021

Influence of the T-helper epitope on the titre and affinity of antibodies to B-cell epitopes after co-immunization

1 reference

https://api.crossref.org/works/10.1016/S0958-1669(97)80066-3

7 January 2021

Protection against morbillivirus-induced encephalitis by immunization with a rationally designed synthetic peptide vaccine containing B- and T-cell epitopes from the fusion protein of measles virus.

1 reference

https://api.crossref.org/works/10.1016/S0958-1669(97)80066-3

7 January 2021

Immunogenicity of poliovirus B and T cell epitopes presented by hybrid porcine parvovirus particles

1 reference

https://api.crossref.org/works/10.1016/S0958-1669(97)80066-3

7 January 2021

Development of sporozoite vaccines

1 reference

https://api.crossref.org/works/10.1016/S0958-1669(97)80066-3

7 January 2021

Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine

1 reference

https://api.crossref.org/works/10.1016/S0958-1669(97)80066-3

7 January 2021

Study of the safety and immunogenicity of the synthetic malaria SPf66 vaccine in children aged 1-14 years

1 reference

https://api.crossref.org/works/10.1016/S0958-1669(97)80066-3

7 January 2021

Field trials of an asexual blood stage malaria vaccine: studies of the synthetic peptide polymer SPf66 in Thailand and the analytic plan for a phase IIb efficacy study.

1 reference

https://api.crossref.org/works/10.1016/S0958-1669(97)80066-3

7 January 2021

Humoral and cellular immune responses to synthetic peptides from the Plasmodium falciparum blood-stage antigen, Pf155/RESA, in Cameroonian women.

1 reference

https://api.crossref.org/works/10.1016/S0958-1669(97)80066-3

7 January 2021

Influence of adjuvants on protection induced by a recombinant fusion protein against malarial infection

1 reference

https://api.crossref.org/works/10.1016/S0958-1669(97)80066-3

7 January 2021

Transmission blocking immunity in Plasmodium vivax malaria: antibodies raised against a peptide block parasite development in the mosquito vector

1 reference

https://api.crossref.org/works/10.1016/S0958-1669(97)80066-3

7 January 2021

Immunization of mice and baboons with the recombinant Sm28GST affects both worm viability and fecundity after experimental infection with Schistosoma mansoni

1 reference

https://api.crossref.org/works/10.1016/S0958-1669(97)80066-3

7 January 2021

Genetic control of immune response to a purified Schistosoma mansoni antigen. II. Establishment and characterization of specific I-A and I-E restricted T-cell clones

1 reference

https://api.crossref.org/works/10.1016/S0958-1669(97)80066-3

7 January 2021

Dendritic Cells as Carriers for a Cytotoxic T-Lymphocyte Epitope-Based Peptide Vaccine in Protection Against a Human Papillomavirus Type 16-Induced Tumor

1 reference

https://api.crossref.org/works/10.1016/S0958-1669(97)80066-3

7 January 2021

Vaccine therapy for cancer

1 reference

https://api.crossref.org/works/10.1016/S0958-1669(97)80066-3

7 January 2021

New treatment options for patients with melanoma: review of melanoma-derived T-cell epitope-based peptide vaccines.

1 reference

https://api.crossref.org/works/10.1016/S0958-1669(97)80066-3

7 January 2021

Structurally defined synthetic cancer vaccines: analysis of structure, glycosylation and recognition of cancer associated mucin, MUC-1 derived peptides

1 reference

https://api.crossref.org/works/10.1016/S0958-1669(97)80066-3

7 January 2021

Ex vivo ras peptide vaccination in patients with advanced pancreatic cancer: results of a phase I/II study

1 reference

https://api.crossref.org/works/10.1016/S0958-1669(97)80066-3

7 January 2021

HIV-1 p17 synthetic peptide vaccine HGP-30: induction of immune response in human subjects and preliminary evidence of protection against HIV challenge in SCID mice

27

1 reference

https://api.crossref.org/works/10.1016/S0958-1669(97)80066-3

Controlling schistosomiasis by vaccination: A realistic option?

12 November 2024

51

1 reference

https://api.crossref.org/works/10.1016/S0958-1669(97)80066-3

A short synthetic peptide (DTRPAP) induces anti-mucin (MUC-1) antibody, which is reactive with human ovarian and breast cancer cells

12 November 2024

65

1 reference

https://api.crossref.org/works/10.1016/S0958-1669(97)80066-3

12 November 2024

Identifiers

1 reference

release_kdx4x2efn5az7gpm3mwgafzs7m

4 October 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/kdx4x2efn5az7gpm3mwgafzs7m

24 November 2022

mapped directly with Wikidata item

1 reference